Haematology‐Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology University of Southern Denmark and Odense University Hospital Odense Denmark
Auto-generated profile, based on publicly available information
Karen Juul-Jensen
Haematology‐Pathology Research Laboratory, Research Unit for Haematology and Research Unit for Pathology University of Southern Denmark and Odense University Hospital Odense Denmark
Currently, the International Prognostic Index (IPI) is the most used and reported model for prognostication in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). IPI-like variations have been proposed, but only a few have been validated in different populations (e.g., revised IPI (R-IPI), National Comprehensive Cancer Network IPI (NCCN-IPI)). We aimed to validate and compare different IPI-like variations to identify the model with the highest predictive accuracy for survival in newly diagnosed DLBCL patients. We included 5126 DLBCL patients treated with immunochemotherapy with available data required by 13 different prognostic models. All models could predict survival, but NCCN-IPI consistently provided high levels of accuracy. Moreover, we found similar 5-year overall survivals in the high-risk group (33.4%) compared to the original validation study of NCCN-IPI. Additionally, only one model incorporating albumin performed similarly well but did not outperform NCCN-IPI regarding discrimination (c-index 0.693). Poor fit, discrimination, and calibration were observed in models with only three risk groups and without age as a risk factor. In this extensive retrospective registry-based study comparing 13 prognostic models, we suggest that NCCN-IPI should be reported as the reference model along with IPI in newly diagnosed DLBCL patients until more accurate validated prognostic models for DLBCL become available.
1 May 2021 in Critical Reviews in Oncology/Hematology
Background: Diffuse large B‐cell lymphoma (DLBCL) is the most common form of lymphoma. European guidelines recommend FDG‐PET/CT for staging and end of treatment (EOT) response assessment, mid‐treatment response assessment is optional. We compared the Lugano classification and PET Response Criteria In Solid Tumours (PERCIST) for FDG‐PET/CT response assessment in DLBCL head‐to‐head.Methods: We retrospectively included patients with DLBCL who underwent first‐line R‐CHOP(‐like) therapy (2013−2020). Interim and EOT FDG‐PET/CT response were reevaluated using the Lugano classification and PERCIST. Response was dichotomized into complete metabolic response (CMR) versus non‐CMR (interim and EOT) and responders versus nonresponders (interim only). The cutoff for nonresponse at interim was a Deauville score of 5 (DS5) with the Lugano classification and a partial metabolic response with ≤66% reduction in SULpeak using PERCIST (PERCIST66).Results: In multivariable Cox regression (N = 170), DS5 at interim, PERCIST66 at interim, non‐CMR at EOT with the Lugano classification and non‐CMR at EOT with PERCIST were predictive of progression‐free survival (PFS). The Lugano classification and PERCIST agreed perfectly at interim and EOT and with 98.4% for the identification of nonresponders at interim. The accuracy for predicting events within 2 years of diagnosis was 84.2% for DS‐5 at interim, 87.6% for PERCIST66 at interim, 86% for non‐CMR with the Lugano classification at EOT and 83.3% for non‐CMR with PERCIST at EOT.Conclusion: The Lugano classification and PERCIST were equally predictive of PFS. Nonresponse at interim and non‐CMR at EOT were predictive of poor PFS with comparable accuracy for predicting events within 2 years.
8 September 2025 in European Journal of Haematology
Background: Clonotyping of immunoglobulin heavy chain (IGH) gene rearrangements is critical for diagnosis, prognostication, and measurable residual disease monitoring in chronic lymphocytic leukemia (CLL). Although short‐read next‐generation sequencing (NGS) platforms, such as Illumina MiSeq, are widely used, they face challenges in spanning full VDJ rearrangements. Long‐read sequencing via Oxford Nanopore Technologies (ONT) offers a potential alternative using the compact and cost‐effective flow cells. Methods: We evaluated IGH clonotyping in samples from 13 CLL patients using ONT MinION with Flongle flow cells and super‐accuracy GPU‐based base calling (Dorado), comparing results to MiSeq‐based LymphoTrack assays. Amplicons were generated using the IGH FR1 assay and analyzed using Smith‐Waterman alignment and IgBlast tools. Results: All major and minor clonotypes identified by MiSeq were matched with 100% sequence identity using Nanopore sequencing. Clonal burden estimates were strongly correlated (Pearson ρ = 0.87, p < 10 −4 ), although with considerable variability. Somatic hypermutation status was reliably assessed with super‐accuracy base calling (Q30: 76%). Fast or CPU‐only base calling was insufficient for accurate mutation analysis. Conclusion: Nanopore sequencing enables accurate and rapid IGH clonotyping in CLL, offering comparable performance to MiSeq with lower cost and laboratory footprint. This supports its potential utility in routine and decentralized hematopathology workflows.